How Quartolio Uncovered 100+ Drugs For COVID-19 Clinical Trials Based On Historical Coronavirus Research

Challenge

COVID-19 research is growing exponentially, and current tools don’t allow scientists to gain insight at the scale of its growth, creating missed opportunities

Challenge

COVID-19 research is growing exponentially, and current tools don’t allow scientists to gain insight at the scale of its growth, creating missed opportunities

Outcome

Quartolio’s Coronavirus Core ™ synthesizes insights from current and historical coronavirus research, providing real-time research leads for drug, antibody, and comorbidity discovery

Outcome

Quartolio’s Coronavirus Core ™ synthesizes insights from current and historical coronavirus research, providing real-time research leads for drug, antibody,and comorbidity discovery

29M +
Cases
930K +
Deaths
1.9K +
Clinical Trials
150 +
Countries w/ Trials
5K +
Articles/Week

Problem

Exponetial Data, Traditional Tools

The Age of Insight is here. And no better time than now: more than 29 million confirmed global COVID-19 cases, and over 930,000 deaths.

In response, the world’s scientists, biotech companies, and publishers are collaborating at an unprecedented scale and speed. Information, including datasets, preprints, and articles are being produced daily, and dozens of efforts have been launched in order to keep up with the pace.

From manual curation and annotation efforts from the American Society of Microbiology and the Cochrane Crowd, to organizations building specialized search engines, the scientific community is seeking deeper insight into COVID-19 research.

As a product of the Age of Information, search engines have a focused objective to find the needle in the haystack, with little ability to make sense of the hay. COVID-19 preprints and publications are doubling every 14 days, with over 5000 produced in a week. Millions of documents, and petabytes of data are piling on, leaving scientists in the same position of learning only from the documents that they have time to read.

Our Solution

Synthesis > Search

Founded in 2016, Quartolio reimagines research discovery with a focus on uncovering research leads and actionable answers in scientific documents. Leveraging Synthesis, our proprietary stack of Artificial Intelligence technologies, documents are transformed into contextual data.

With the novel coronavirus becoming evident in the literature in early February of this year, we put Quartolio to work on historical coronavirus research. Could coronavirus research from the past provide valuable, even predictive insights for SARS-CoV-2, the virus that causes COVID-19?

Quartolio’s job was to learn from historical research in order to give deeper context to the growing body of recent research. We leveraged Open Access articles, clinical trials, patents, and other documents to automate the formation of the Coronavirus Core ™. In March, the White House Office of Science and Technology Policy, with an assist from a consortium of publishers and tech companies, issued a call to the world’s technologist to devise a solution that would allow scientists to rapidly gather insight from COVID-19 research.

With that call came the release of the CORD-19 Open Research Dataset, a collection of over 200,000 COVID-19 articles and resources, centralizing additional coronavirus research for contextual analysis and synthesis.

Results

Actionable Answers

Around the clock, Quartolio worked to learn about the most important concepts in all of Coronavirus research.

These concepts surface, becoming research targets, subject to expansive computational query.

In line with scientists fighting COVID-19, Quartolio's research leads uncovered over 100 drugs that are currently in clinical trials.

Based on chloroquine, research leads include Dipyridamole, Adalimumab, and Lopinavir/Ritonavir. One of the leading recommendations was Dexamethasone, which is notable as a recent breakthrough.

With Dexamethasone as the research target, Quartolio also provided research leads for dozens of drugs that are also currently in clinical trials. In addition, Quartolio recommended dozens of potential drugs based on Dexamethasone, including anticoagulants, as well as drugs in the Carboxylic acids class, amongst others.

Research Target

Chloroquine

Research Leads

122/3045 4%

Based on Chloroquine as the Research Target, Quartolio recommended 4% of the treatments of the 3045 clinical trials for COVID-19

Research Target

Dexamethasone

Research Leads

128/3045 4%

Based on Dexamethasone as the Research Target, Quartolio recommended 4% of the treatments of the 3045 clinical trials for COVID-19

Automatically, Quartolio digs deeper into research leads, identifying acrylamide, as a common compound associated with other drugs recommended based on Dexamethasone; including Tamoxifen and Methotrexate, which have also been explored as COVID-19 solutions.

With these results, Quartolio just scratches the surface of billions of insights that are automatically refined and curated based on your area of focus.

Narrowing in on HCoV-NL63, a coronavirus strain with zoonotic origins tied to bats, Quartolio’s research leads for signs and symptoms include: sore throat, fever, fatigue, diarrhea, hemoptysis, cough, and respiratory symptoms.

Exploring the Comorbidity Component of the Coronavirus Core ™, with cardiovascular disease as the target; urinary tract infections, endocarditis, hyperlipidemia, and acute renal failure are just some of the research leads that are recommended.

Research Target

encephalitis

Research Leads

adenovirus
atherosclerosis
autoimmune disease
diabetes
hepatitis
HIV
influenza
Klebsiella pneumoniae
leishmaniasis
lupus
malaria
rheumatoid arthritis
tuberculosis
Vibrio cholerae
yellow fever

Research Target

CD45RA

Research Leads

Granulocyte
Fibroblast
white blood cell
osteoclast
sickle cell
islet cell
T-helper cells
osteoblast
HT29
Eosinophil
Reticulocyte
dendritic cells
endothelial cells
K-562
Purkinje cells

In pace with COVID-19’s exponential spread, data to end its devastation has grown beyond the scope of search as the endgame. Meeting the moment, Quartolio helps researchers gather rapid, responsive research insights that can cut literature search by 90% while uncovering precise answers to questions that you may not know to ask, yet.

Quartolio forms Cores across disciplines, with Cross-Core Computation enabled for expansive cross-disciplinary discovery. In a truly multi-dimensional fashion, expanded breadth of insight is paired with expanded depth of insight. With demanding computational needs, we built Quartolio to scale insight, whether you’re a lab of 1 or 1000. QPU, Quartolio Processing Units facilitate varying depths of insight based on your needs.

R&D stakeholders can access the Coronavirus Core via BIOME for Business Intelligence, Cortex for free to flexible options for streaming insights, and Cerebra, for Enterprise Drug, Antibody, Genomic, and Comorbidity discovery.

COVID-19’s effects are far reaching. Both, for its systemic, often lingering symptoms, and exponential spread in populations around the globe. The tools that we use to tackle its mounting reach and research must match its scale. Quartolio is a handshake between Artificial Intelligence and Human Intelligence. As it augments your insight, its intelligence is augmented, producing improved speed and precision for faster breakthroughs.